Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
$1.21
-3.2%
$1.22
$0.51
$5.01
$21.15M1.962.20 million shs161,426 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.46
+1.5%
$3.22
$2.57
$6.88
$21.07M0.639,061 shs3,739 shs
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
$7.33
-2.1%
$7.32
$3.34
$16.50
$20.86M1.132,973 shs4,594 shs
XTLB
XTL Biopharmaceuticals
$1.21
+7.1%
$3.99
$0.86
$3.05
$6.54M1.0923,588 shsN/A
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-3.20%-1.63%-3.97%+14.15%+71.63%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
+1.47%+0.61%+4.85%-1.14%-45.85%
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
-2.14%+1.81%-3.29%+33.27%-20.30%
XTLB
XTL Biopharmaceuticals
-0.82%-7.98%+6.61%+0.83%-43.46%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
2.9531 of 5 stars
3.75.00.00.02.60.00.6
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.8211 of 5 stars
0.03.00.00.02.21.70.6
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
3.2239 of 5 stars
3.55.00.00.02.21.70.6
XTLB
XTL Biopharmaceuticals
0.1761 of 5 stars
0.03.00.00.00.01.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
3.33
Buy$14.001,057.02% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
3.00
Buy$40.00445.70% Upside
XTLB
XTL Biopharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/AN/AN/AN/A$0.13 per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.19N/AN/A$13.32 per share0.26
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
$11.54M1.77N/AN/A$10.36 per share0.71
XTLB
XTL Biopharmaceuticals
$450K14.65N/AN/A$1.00 per share1.21
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$7.85M-$0.51N/AN/AN/AN/A-341.08%-272.93%8/12/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%N/A
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
-$10.58M-$4.70N/AN/AN/A-107.78%-43.98%-35.28%8/15/2025 (Estimated)
XTLB
XTL Biopharmaceuticals
-$1.03MN/A0.00N/AN/AN/AN/AN/A

Latest XTLB, MIRA, NAII, and SLGL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/23/2025Q1 2025
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
N/A-$3.20N/A-$3.20N/A$1.03 million
5/14/2025Q1 2025
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$0.15-$0.11+$0.04-$0.11N/AN/A
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
3/28/2025Q4 2024
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$0.29-$0.15+$0.14-$0.15N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
N/AN/AN/AN/AN/A
XTLB
XTL Biopharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/A
12.86
12.86
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
N/A
5.12
5.12
XTLB
XTL Biopharmaceuticals
N/A
0.61
0.61
CompanyEmployeesShares OutstandingFree FloatOptionable
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
216.92 million15.80 millionNot Optionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
502.79 million933,000Optionable
XTLB
XTL Biopharmaceuticals
N/A5.45 million3.87 millionNot Optionable

Recent News About These Companies

XTL Biopharmaceuticals names Noam Band as CEO
XTL Biopharmaceuticals Appoints Noam Band as CEO
XTL Biopharmaceuticals Ltd (XTLB)
XTL Biopharmaceuticals Ltd XTLB
XTL Biopharmaceuticals acquires AI firm Social Proxy
XTL Biopharmaceuticals Ltd. (XTLB.TA)
XTL Biopharmaceuticals Ltd. ADR
Dow Surges 350 Points; Fed Holds Rates Steady
Crude Oil Surges 2%; Signet Jewelers Shares Spike Higher
XTL To Aquire The Social Proxy
XTL Biopharmaceuticals Ltd ADR (XTLB)

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRA Pharmaceuticals stock logo

MIRA Pharmaceuticals NASDAQ:MIRA

$1.21 -0.04 (-3.20%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$1.20 0.00 (-0.41%)
As of 06/26/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.45 +0.04 (+1.17%)
As of 06/26/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

Sol-Gel Technologies stock logo

Sol-Gel Technologies NASDAQ:SLGL

$7.33 -0.16 (-2.14%)
Closing price 06/26/2025 03:57 PM Eastern
Extended Trading
$7.24 -0.09 (-1.23%)
As of 06/26/2025 06:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

XTL Biopharmaceuticals NASDAQ:XTLB

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.